FAST logo for screen only vector TRANSPARENT.png
FAST and SFARI to launch International Angelman Syndrome Research Council (INSYNC-AS)
February 19, 2021 09:00 ET | FAST (Foundation for Angelman Syndrome Therapeutics)
DOWNERS GROVE, Ill., Feb. 19, 2021 (GLOBE NEWSWIRE) -- FAST (Foundation for Angelman Syndrome Therapeutics) and the Simons Foundation Autism Research Initiative (SFARI) today announced a...
AskBio-Logo.jpg
AskBio Enters Research Collaboration and Licensing Agreement with University of North Carolina (UNC) for Angelman Syndrome
March 18, 2020 09:27 ET | Asklepios BioPharmaceutical, Inc.
RESEARCH TRIANGLE PARK, N.C. and CHAPEL HILL, N.C., March 18, 2020 (GLOBE NEWSWIRE) -- Asklepios BioPharmaceutical, Inc. (AskBio), a leading clinical-stage adeno-associated virus (AAV) gene therapy...
LIXTE.jpg
Lixte Biotechnology’s PP2A Inhibitor, LB-100, Improves Brain Function and Motor Impairment in a Mouse Model of Angelman Syndrome, a Rare Human Neurodevelopmental Disorder
June 25, 2019 09:35 ET | Lixte Biotechnology Holdings, Inc.
EAST SETAUKET, NY, June 25, 2019 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT) noted that a group of neuroscientists in China and Japan reported that Lixte’s lead clinical...
GeneTx Biotherapeutics receives FDA orphan-drug designation for Angelman syndrome treatment
March 27, 2018 13:26 ET | GeneTx Biotherapeutics LLC.
DOWNERS GROVE, Ill., March 27, 2018 (GLOBE NEWSWIRE) -- The U.S. Food and Drug Administration has granted orphan-drug designation to GeneTx Biotherapeutics LLC’s GTX-101 for the treatment of...